stars 1 stars 2 stars 3

We improve patient outcomes by empowering healthcare professionals to make better informed clinical decisions, leading to more efficient patient triage. The suPAR biomarker predicts negative patient outcomes across diseases by measuring the immune system’s activation level. suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at hospital emergency departments. suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better informed decisions across diseases, backed by reliable biological data. Implementing suPAR in clinical care saves critical resources and valuable time, and results in vastly reduced healthcare costs, more efficient triage, and better patient outcomes. At hospital emergency departments, suPAR delivers faster and safer patient discharges, reduces readmissions, avoids unnecessary admissions, and lowers hospital length of stay. Seamlessly implemented by clinician and laboratory technicians, suPARnostic products fit existing workflows in hospitals, are approved for all the major clinical chemistry analyzers, and delivers results in less than 20 minutes.

ViroGates Questions

The ViroGates annual revenue was $1 million in 2026.

Jakob Knudsen is the CEO of ViroGates.

8 people are employed at ViroGates.

The NAICS codes for ViroGates are [325413, 325, 32541, 3254, 32].

The SIC codes for ViroGates are [283, 28].

Top ViroGates Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users